The pathophysiology of psoriasis and psoriatic arthritis (PsA) is dependent on a multistep
process that leads to chronic or recurrent inflammation1, 2, 3. Blockade of cytokines …

Ustekinumab is a human monoclonal antibody that targets the p40 subunit of both
interleukin 12 (IL-12) and IL-23 and inhibits their activity. IL-12 and IL-23 have a key role in …

SIR, PsA and psoriasis are closely related chronic inflammatory conditions leading to multi-
tissue involvement. Polymorphisms in genes regulating TNFa and the IL-23 and-17 (IL …

A 47 year old man presented with seven years of severe psoriatic polyarticular arthritis of
progressive, symmetrical, and additive course, aVecting the shoulders, elbows, wrists …

Discussion This patient, receiving concomitant treatment with ustekinumab and etanercept,
experienced a great reduction in both the signs and symptoms of psoriatic disease. In this …

SIR, Psoriasis and PsA share common pathophysiological mechanisms. The mutual role of
Th17 cells is supported by the therapeutic efficacy of ustekinumab, an IL-12/23 mAb, in PsO …

Dear Editor: Erythrodermic psoriasis is a severe form of psoriasis, presenting as prominent
erythema rather than thick scales, affecting the entirebody including the face, trunk …

Following the pivotal report that outlined unique disease features half a century ago (1),
investigators in the field of psoriatic arthritis (PsA) have extrapolated clinical trial data and …

In recent years there has been a surge of interest in the treatment of chronic inflammatory
disorders as a result of the development and application of targeted biological therapies …

Recently, a case of severe pustular psoriasis during infliximab therapy has been reported in
your journal. 1 In the last year, we have observed 3 cases of psoriatic skin lesions after …